Ontario Genomics Institute /
2012 Annual Report

header_tcag

The genetic blueprint for all living organisms is encoded in DNA, a sequence of molecules made up of adenine (A), cytosine (C), guanine (G) and thymine (T).

Consolidated Statement of Cash Flows

Year ended March 31, 2012, with comparative figures for 2011
  2012 2011
Cash provided by (used in):
Operations:
Deficiency of revenue over expenses (3,017) (154,517)
Items not involving cash:
Amortization of deferred contributions (19,480,520) (20,845,810)
Amortization of lease inducement (13,500)
Write down of long-term advances (note 3) 300,000 100,000
Loss on disposal of long-term advances (note 3) 50,753
Amortization of capital assets 17,206 62,575
Loss on disposal of capital assets 1,416
(19,166,331) (20,799,083)
Change in non-cash assets and liabilities:
Accounts receivable 111,747 (91,589)
Advances to genomics research projects (1,904,164) 15,513
Deposits and prepaid expenses 4,800 9,334
Accounts payable and accrued liabilities 5,778 22,072
Deferred contributions 20,163,205 19,422,893
(784,965) (1,420,860)
Investments:
Increase in long-term advances (note 3) (175,000) (225,000)
Proceeds from long-term advances (note 3) 50,000 49,247
Purchase of capital assets (18,692)
(143,692) (175,753)
Decrease in cash (928,657) (1,596,613)
Cash, beginning of year 4,819,079 6,415,692
Cash, end of year 3,890,422 4,819,079

See accompanying notes to consolidated financial statements.